🚀 VC round data is live in beta, check it out!
NeuroPace Valuation Multiples
Discover revenue and EBITDA valuation multiples for NeuroPace and similar public comparables like Revenio Group, Mesa Laboratories, Orthofix Medical, Beta Bionics and more.
NeuroPace Overview
About NeuroPace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Founded
1997
HQ
Employees
184
Website
Financials (LTM)
EV
$554M
NeuroPace Financials
NeuroPace reported last 12-month revenue of $100M and negative EBITDA of ($7M).
In the same LTM period, NeuroPace generated $80M in gross profit, ($7M) in EBITDA losses, and had net loss of ($21M).
Revenue (LTM)
NeuroPace P&L
In the most recent fiscal year, NeuroPace reported revenue of $100M and EBITDA of ($5M).
NeuroPace expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $100M | XXX | $100M | XXX | XXX | XXX |
| Gross Profit | $80M | XXX | $77M | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 77% | XXX | XXX | XXX |
| EBITDA | ($7M) | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | (7%) | XXX | (5%) | XXX | XXX | XXX |
| EBIT Margin | (16%) | XXX | (16%) | XXX | XXX | XXX |
| Net Profit | ($21M) | XXX | ($21M) | XXX | XXX | XXX |
| Net Margin | (21%) | XXX | (21%) | XXX | XXX | XXX |
| Net Debt | — | — | $37M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NeuroPace Stock Performance
NeuroPace has current market cap of $544M, and enterprise value of $554M.
Market Cap Evolution
NeuroPace's stock price is $16.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $554M | $544M | 0.0% | XXX | XXX | XXX | $-0.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNeuroPace Valuation Multiples
NeuroPace trades at 5.6x EV/Revenue multiple, and (76.0x) EV/EBITDA.
EV / Revenue (LTM)
NeuroPace Financial Valuation Multiples
As of April 19, 2026, NeuroPace has market cap of $544M and EV of $554M.
Equity research analysts estimate NeuroPace's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NeuroPace has a P/E ratio of (25.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $544M | XXX | $544M | XXX | XXX | XXX |
| EV (current) | $554M | XXX | $554M | XXX | XXX | XXX |
| EV/Revenue | 5.6x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | (76.0x) | XXX | (110.6x) | XXX | XXX | XXX |
| EV/EBIT | (33.8x) | XXX | (33.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | 7.2x | XXX | XXX | XXX |
| P/E | (25.8x) | XXX | (25.4x) | XXX | XXX | XXX |
| EV/FCF | (56.7x) | XXX | (48.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NeuroPace Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NeuroPace Margins & Growth Rates
NeuroPace's revenue in the last 12 month grew by 6%.
NeuroPace's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.5M for the same period.
NeuroPace's rule of 40 is (14%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NeuroPace's rule of X is (15%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
NeuroPace Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | (7%) | XXX | (5%) | XXX | XXX | XXX |
| EBITDA Growth | 38% | XXX | 152% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (14%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (15%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 48% | XXX | 47% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19% | XXX | 19% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 28% | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 94% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NeuroPace Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| NeuroPace | XXX | XXX | XXX | XXX | XXX | XXX |
| Revenio Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesa Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Orthofix Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Beta Bionics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sofwave Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeuroPace M&A Activity
NeuroPace acquired XXX companies to date.
Last acquisition by NeuroPace was on XXXXXXXX, XXXXX. NeuroPace acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NeuroPace
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNeuroPace Investment Activity
NeuroPace invested in XXX companies to date.
NeuroPace made its latest investment on XXXXXXXX, XXXXX. NeuroPace invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NeuroPace
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NeuroPace
| When was NeuroPace founded? | NeuroPace was founded in 1997. |
| Where is NeuroPace headquartered? | NeuroPace is headquartered in United States. |
| How many employees does NeuroPace have? | As of today, NeuroPace has over 184 employees. |
| Who is the CEO of NeuroPace? | NeuroPace's CEO is Joel Becker. |
| Is NeuroPace publicly listed? | Yes, NeuroPace is a public company listed on Nasdaq. |
| What is the stock symbol of NeuroPace? | NeuroPace trades under NPCE ticker. |
| When did NeuroPace go public? | NeuroPace went public in 2021. |
| Who are competitors of NeuroPace? | NeuroPace main competitors are Revenio Group, Mesa Laboratories, Orthofix Medical, Beta Bionics. |
| What is the current market cap of NeuroPace? | NeuroPace's current market cap is $544M. |
| What is the current revenue of NeuroPace? | NeuroPace's last 12 months revenue is $100M. |
| What is the current revenue growth of NeuroPace? | NeuroPace revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of NeuroPace? | Current revenue multiple of NeuroPace is 5.6x. |
| Is NeuroPace profitable? | No, NeuroPace is not profitable. |
| What is the current EBITDA of NeuroPace? | NeuroPace has negative EBITDA and is not profitable. |
| What is NeuroPace's EBITDA margin? | NeuroPace's last 12 months EBITDA margin is (7%). |
| What is the current EV/EBITDA multiple of NeuroPace? | Current EBITDA multiple of NeuroPace is (76.0x). |
| What is the current FCF of NeuroPace? | NeuroPace's last 12 months FCF is ($10M). |
| What is NeuroPace's FCF margin? | NeuroPace's last 12 months FCF margin is (10%). |
| What is the current EV/FCF multiple of NeuroPace? | Current FCF multiple of NeuroPace is (56.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.